JDRF
Pharma leadership strategies for talent, AI adoption, and continuous learning
In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
Sanofi announces phase 3 study data for infantile-onset Pompe disease
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form
Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses
SPMS is a debilitating stage of MS where patients experience increasing levels of disability
Sanofi appoints Paulo Fontoura as Global Head of R&D
Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche
Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector
It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
New benchmark reveals significant digital maturity gap across UK POM companies’ product-information estates
A new benchmark maps 100 UK prescription medicine companies across five maturity bands and finds a market at very different stages of digital development
Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes
The treatment can be used to delay the onset of clinical type 1 diabetes
Why pharma website projects stall long before compliance becomes the problem
Pharma teams often blame compliance when digital projects slow down. In reality, the bigger issue is usually weaker ownership, unclear review models and content structures that were never designed for...
Novo Nordisk and Vivtex partner in deal worth up to $2.1bn
The companies aim to develop next-generation oral medicines for obesity and diabetes
Sanofi announces positive results for venglustat in type 3 Gaucher disease
There are currently no approved treatments for the neurological symptoms of this disease